

Corbion

YTD/Q3 2026 RESULTS

OLIVIER RIGAUD (CEO)
PETER KAZIUS (CFO)

28-Oct-2026

This presentation contains forward-looking statements with respect to Corbion's future performance and position. Such statements are based on current expectations, estimates, and projections of Corbion and information currently available to the company. Corbion cautions readers that such statements involve certain risks and uncertainties that are difficult to predict and therefore it should be understood that many factors can cause actual performance and position to differ materially from these statements. Also, for a variety of reasons including many factors outside the control of Corbion, there can be no guarantee that any proposed strategic initiatives will be completed within the expected time frame or at all. Nor can there be any guarantee that Corbion will be able to realize any of the potential strategic benefits, synergies, or opportunities, or any guarantee that shareholders will achieve any particular level of return in relation thereto. Corbion has no obligation to update the statements contained in this presentation, unless required by law.

More details on Corbion's H1 2026 financial performance can be found in the Q3 2026 press release. A more comprehensive discussion of the risk factors affecting Corbion's business is available in the company's Annual Report 2025.

This presentation to investors includes alternative performance measures (APMs), and information that is presented in accordance with IFRS as issued by the International Accounting Standards Board ('IFRS figures').

YTD/Q3 2026 Highlights

- **YTD Organic sales growth of +3.9% to € 971.6 million (Q3: +7.6%, € 340.5 million)**
  - Volume/mix +5.3% (Q3: +7.9%)
  - Pricing -1.4% (Q3: -0.3%)
- **YTD Adjusted EBITDA € 152.9 million (Q3: € 64.1 million)**
- **Health & Nutrition: Q3 organic sales growth of +20.0% and Adjusted EBITDA margin increased +400 bps to +38.1%, driven by strong Nutrition volume recovery and favorable mix**
- **Functional Ingredients & Solutions: YTD organic sales growth at high-end of forecasted range at +3.8% (Q3: +4.0%) and Adjusted EBITDA margin up +170 bps to 11.0% (Q3: 12.5%).**
- **Strong free cash flow generation in Q3**
- **FY 2026 outlook affirmed**

Organic sales growth
+3.9% (YTD)
+7.6% (Q3)

Adj. EBITDA margin
15.7% (YTD)
18.8% (Q3)

Free Cash Flow
€ 57.0 m (YTD)
€ 61.0 m (Q3)

Corbion

Sales growth per segment in YTD/Q3 2026

Sales growth	Vol./Mix	Price	Organic		FX	Acq./ Div.	Total growth
YTD 2026 vs YTD 2025							
- Functional Ingredients & Solutions	+4.1%	-0.3%	+3.8%		-2.6%	0.0%	+1.2%
- Health & Nutrition	+9.0%	-4.9%	+4.1%		-1.6%	0.0%	+2.5%
Total	**+5.3%**	**-1.4%**	**+3.9%**		**-2.4%**	**0.0%**	**+1.5%**
Q3 2026 vs Q3 2025							
- Functional Ingredients & Solutions	+3.7%	+0.3%	+4.0%		+1.7%	0.0%	+5.7%
- Health & Nutrition	+22.3%	-2.3%	+20.0%		+1.9%	0.0%	+21.9%
Total	**+7.9%**	**-0.3%**	**+7.6%**		**+1.7%**	**0.0%**	**+9.3%**

Corbion


Sales and Adjusted EBITDA: YTD/Q3 2026

€ million	YTD 2026	YTD 2025	YTD Growth		Q3 2026	Q3 2025	Q3 Growth
Sales							
- Functional Ingredients & Solutions	748.7	739.8	+1.2%		256.0	242.3	+5.7%
- Health & Nutrition	222.9	217.4	+2.5%		84.5	69.3	+21.9%
Total Net Sales	**971.6**	**957.2**	**+1.5%**		**340.5**	**311.6**	**+9.3%**
Adjusted EBITDA							
- Functional Ingredients & Solutions	82.6	85.2	-3.1%		31.9	26.1	+22.2%
- Health & Nutrition	70.3	71.1	-1.1%		32.2	23.6	+36.4%
Total Adjusted EBITDA	**152.9**	**156.3**	**-2.2%**		**64.1**	**49.7**	**+29.0%**
Adjusted EBITDA margin							
- Functional Ingredients & Solutions	11.0%	11.5%	-50 bps		12.5%	10.8%	+170 bps
- Health & Nutrition	31.5%	32.7%	-120 bps		38.1%	34.1%	+400 bps
Total Adjusted EBITDA margin	**15.7%**	**16.3%**	**-60 bps**		**18.8%**	**15.9%**	**+290bps**


Corbion

YTD Sales and Adjusted EBITDA development

Sales YTD



Adjusted EBITDA YTD



*Continued operations for 2024

Corbion

Functional Ingredients & Solutions

YTD organic sales growth of +3.8% (Q3: +4.0%)

- **Volume/mix +4.1% (Q3: +3.7%)**
  - **Food**: growth in natural preservation, vinegars and high-protein bakery, with soft meat and confectionery demand. Natural mold inhibitors and enzyme blends continued to grow.
  - **Biochemicals**: strong YTD and Q3 sales growth continued from H1
  - **Lactic Acid to PLA**: higher volumes to the JV drove growth, with lower pass-through pricing
- **Pricing -0.3% YTD (Q3: +0.3%),** with Q3 pricing initiatives supporting the increase


Adjusted EBITDA margin 11.0%, -50 bps (Q3: 12.5%, +170 bps)

- YTD margin pressure from lower-margin business mix.
- Q3 margin improvement driven by cost-reduction initiatives and operational efficiencies.
- Sequential margin increase versus Q2 +100bps

€ million	YTD 2026	YTD 2025	Q3 2026	Q3 2025
Sales	748.7	739.8	256.0	242.3
Organic growth	+3.8%	+1.5%	+4.0%	+0.8%
Adjusted EBITDA	82.6	85.2	31.9	26.1
Adjusted EBITDA margin	11.0%	11.5%	12.5%	10.8%

Org sales growth - Functional Ingredients & Solutions
(%)


YTD +3.8%



Q3 volume/mix growth of 3.7%

Adjusted EBITDA margin Functional Ingredient & Solutions
(%)

YTD 11.0%



Q3 EBITDA margin up +170 bps to 12.5%

Corbion


Health & Nutrition

YTD organic sales growth of +4.1% (Q3: +20.0%)


- **Volume/mix +9.0% (Q3: +22.3%)**
  - **Nutrition**: Strong Q3 growth reflected anticipated volume phasing from H1 2026. Higher fish oil prices lifted omega-3 DHA prices, with new-customer sales mainly reflected in mix.
  - **Pharma**: YTD and Q3 sales declined on lower volume/mix and 2026 destocking at key customers in North and Latin America.
  - **Biomaterials**: YTD sales rose on higher volume/mix and pricing. In October, Medincell and Teva announced FDA approval of WELTRUZA™ (olanzapine), the first and only once-monthly subcutaneous olanzapine for adults with schizophrenia, supporting Corbion's BRIGHT 2030 sales growth ambition.
- **Pricing -4.9% (Q3: -2.3%)**

YTD Adjusted EBITDA margin 31.5%, -120 bps (Q3: 38.1%, +400 bps). YTD 2026 Adjusted EBITDA declined -1.1% to €70.3m but rose at constant currency. Q3 grew 36.4% year-on-year, driven by favorable mix and strong Nutrition volume recovery after phasing.

€ million	YTD 2026	YTD 2025	Q3 2026	Q3 2025
Sales	222.9	217.4	84.5	69.3
Organic growth	+4.1%	+0.1%	+20.0%	-11.2%
Adjusted EBITDA	70.3	71.1	32.2	23.6
Adjusted EBITDA margin	31.5%	32.7%	38.1%	34.1%



Q3 organic sales +20.0% on Nutrition volume phasing



Q3 adj. EBITDA margin 38.1%, +400 bps YoY

WELTRUZA™ is a registered trademark of Teva Pharmaceuticals

Corbion

TotalEnergies Corbion joint venture

YTD organic sales growth +24.2% (Q3: +29.5%)

- Sales €120.7m vs €100.9m YTD 2025 (Q3: €41.6m vs €31.6m).

YTD EBITDA margin 7.7%, -130 bps (Q3: 8.2%, +30 bps)

- EBITDA €9.3m vs €9.1m YTD 2025 (Q3: €3.4m vs €2.5m).

PLA divestment process discontinued


- Offers did not reflect the business's value, strategic position and long-term potential.
- Corbion will develop the business under current ownership and improve performance as PLA market dynamics strengthen.

€ million *	YTD 2026	YTD 2025	Q3 2026	Q3 2025
Sales	120.7	100.9	41.6	31.6
Organic growth	+24.2%	+4.3%	+29.5%	+1.6%
EBITDA	9.3	9.1	3.4	2.5
EBITDA margin	7.7%	9.0%	8.2%	7.9%

*Results on 100% basis. Corbion owns 50% of TotalEnergies Corbion joint venture

Sales - TotalEnergies Corbion


YTD +24.2%



Q3 organic sales growth +29.5%

Adjusted EBITDA margin TotalEnergies Corbion (%)

YTD 7.7%



Q3 EBITDA margin 8.2%, +30 bps YoY

Corbion

FY 2026 guidance maintained

Organic sales growth:	+3-6%
Adjusted EBITDA margin:	>16%
Free Cash Flow*:	€ 85-90 million
CapEx spend 2026-2028:	~6% of sales

- Strong Q3 and Q4 orderbook visibility support full-year guidance.
- FY organic sales growth in both segments: continued Q4 FI&S growth and mid-single-digit-% H&N growth.
- FY Adjusted EBITDA margin >16%. Q4 margins: FI&S below Q3 on seasonality and Middle East-related costs, H&N broadly stable.

* Free Cash Flow = Cash Flow from operating activities -/- Cash Flow from investment activities (excluding acquisitions/disposals)

Corbion

Investor relations

alex.sokolowski@corbion.com

www.corbion.com

+31 20 590 6341